Gilead Sciences' subsidiary Kite Pharma acquired Interius BioTherapeutics for $350 million, gaining access to innovative in vivo CAR-T therapies that genetically modify immune cells directly within the body. This strategic move positions Gilead alongside other major biopharma companies investing in next-generation cell therapies aimed at simplifying manufacturing and broadening patient access. The acquisition expands Gilead's immuno-oncology pipeline and underscores the growing industry focus on in vivo gene-modification approaches.